Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

Dennis J. Slamon,Patrick Neven,S Chia,Peter A. Fasching,Michelino De Laurentiis,Seock-Ah Im,K. Petrakova,G V Bianchi,Francisco J. Esteva,Miguel Martin,Arnd Nusch,Gabe S. Sonke,Luis de la Cruz-Merino,J. Thaddeus Beck,Xavier Pivot,Manu Sondhi,Yingbo Wang,Arunava Chakravartty,Karen Rodriguez-Lorenc,Tetiana Taran,G Jerusalem

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

2020

Abstract Background In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrant alone in postmenopau...

Keywords:

Oncology
Clinical trial
Cancer
Fulvestrant
Progression-free survival
Medicine
MEDLINE
Internal medicine
Ribociclib
Estrogen
Randomized controlled trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

203

Citations